CIK 0001651308
- Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981209416
- Phone
- +41 616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- 4 Open-market sale Chief Executive Officer sold 85,906 shares at an average $84.66 ($7,272,904)
- 4 Open-market sale CMO, Hematology sold 1,600 shares at an average $86.25 ($138,000)
- 4 Open-market sale Chief Executive Officer sold 150,957 shares at an average $80.50 ($12,152,374)
- 4 Open-market sale CMO, Immuno-oncology sold 3,601 shares at an average $82.96 ($298,747)
- 4 Other disposition Director disposed of 49,200 shares (other)
- 4 Grant or award Chief Executive Officer acquired 515,000 shares (grant or award)
- 4 Grant or award Director acquired 410,000 shares (grant or award)
- 4 Shares withheld for taxes CMO, Immuno-oncology gave up 28,185 shares (to pay taxes)
- 4 Open-market buy Director bought 176,056 shares at $71.00 ($12,499,976)
- 4 Open-market sale Director sold 20,000 shares at an average $72.44 ($1,448,704)
- 4 Open-market sale Director sold 10,810 shares at an average $72.15 ($779,900)
- 4 Open-market sale Chief Executive Officer sold 219,400 shares at an average $64.82 ($14,221,125)
- 4 Open-market sale Director sold 35,000 shares at an average $44.95 ($1,573,345)
- 4/A Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Executive Officer sold 98,500 shares at an average $44.16 ($4,349,622)
- 4 Derivatives Options or other derivatives
Page 26 of 29 · 580 filings